Cipla’s net profit surged 78.8% and revenue from operations increased by 7.4% in the March quarter from the same period a year ago.
Brokerage HSBC has maintained its ‘Buy’ rating and has a price target of ₹1,600, seeing an upside of 12.6% from current levels.
“We continue to like Cipla’s healthy outlook in key segments (India, South Africa, the US), delivery on cost efficiencies and prudent capital allocation. Notable pipeline products – inhalers and peptides – provide comfort for the medium-term growth outlook for the US sales,” said HSBC’s analysts in a note to clients.
Jefferies has maintained its ‘Hold’ rating while increasing the price target from ₹1,250 to ₹1,400. “We maintain our Hold rating on the stock, as the company continues to falter on key product launches in the US along with inability to meet its own launch guidance while the stock trades at rich valuation of 24x FY26 EPS,” said Jefferies’ analysts.